HepaTx Corporation is a privately-held biotechnology and regenerative medicine company focused on developing cell-based therapies as alternatives to liver transplantation. Founded in 2015 and headquartered in Palo Alto, California, the company addresses the massive global medical burden of late-stage and end-stage liver disease.
Currently, orthotopic liver transplantation remains the only curative treatment for patients experiencing terminal liver failure. However, the availability of donor organs satisfies only a tiny fraction of the clinical demand, leaving hundreds of thousands of patients worldwide without viable long-term treatment options. HepaTx’s mission is to revolutionize this treatment landscape by supplying a low-cost, scalable, and practical source of functional liver cells capable of preserving or regenerating native organ function.
Core Technology and Scientific Approach
HepaTx’s proprietary platform leverages advanced stem cell differentiation protocols to address the acute shortage of primary human hepatocytes. Rather than relying on embryonic stem cells or induced pluripotent stem cells (iPSCs), which can carry complex regulatory and oncogenic profiles, HepaTx utilizes Mesenchymal Stem Cells (MSCs) derived from adipose (fat) tissue.
The company's core technological workflow involves:
1. Source Material Acquisition: Utilizing discarded lipoaspirate (fat tissue obtained from surgical procedures), providing a highly abundant and ethically uncomplicated source of cellular material.
2. Directed Differentiation: Employing a patented chemical and biological protocol—originally developed and licensed from Stanford University—to coax these adipose-derived stromal cells into functional, hepatocyte-like cells.
3. Targeted Mechanism of Action: Once differentiated, these engineered cells are formulated for direct infusion into the patient's liver via the portal vein. Upon homing into the liver parenchyma, they integrate and function alongside remaining native liver cells, taking over critical metabolic, detoxification, and protein-synthesis activities.
This therapeutic mechanism aims to actively repair damaged tissues, stabilize the biological environment of a failing liver, and potentially reverse the progression of decompensated liver conditions.
Product and Therapeutic Solutions Portfolio
Because HepaTx operates within the advanced cell therapy and regenerative biotechnology sectors, its "products" consist of investigational cellular therapeutics rather than consumer services or off-the-shelf medical devices. Its clinical and preclinical efforts are organized into the following pipelines:
1. Allogeneic "Off-the-Shelf" Hepatocyte Replacement Therapy
The flagship product under development is an allogeneic cell therapy solution. By manufacturing therapeutic cells from healthy donor tissue that can be administered to multiple recipients, HepaTx aims to provide an "on-demand" treatment. This avoids the lengthy delays and high costs associated with patient-specific autologous manufacturing, making the intervention highly viable for emergency use in acute settings.
2. Treatment for Alcohol-Related Hepatitis
HepaTx has positioned its initial clinical focus on alcohol-related hepatitis. This severe form of liver inflammation caused by excessive alcohol consumption can rapidly deteriorate into acute-on-chronic liver failure, carry high short-term mortality rates, and offer very few therapeutic interventions outside of intensive supportive care or emergency transplantation. The engineered hepatocyte-like cells are intended to reduce local inflammation and provide immediate metabolic support to help the organ recover.
3. Solutions for End-Stage Liver Disease (ESLD) and Cirrhosis
The long-term objective of HepaTx's therapeutic line is to address broader indications, including chronic decompensated cirrhosis resulting from non-alcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease or MASLD), viral hepatitis, and metabolic disorders. For these patients, the therapy acts as a regenerative patch to extend survival, improve quality of life, or completely remove the necessity for a traditional organ transplant.
Strategic Partnerships and Clinical Progression
To transition its laboratory-scale breakthroughs into clinical realities, HepaTx relies on deep integration with premier research, manufacturing, and healthcare institutions.
- Mayo Clinic Strategic Collaboration (Late 2024): HepaTx entered into a comprehensive licensing and development agreement with the Mayo Clinic's Center for Regenerative Biotherapeutics. This partnership focuses on advancing HepaTx's stem cell technology into its initial first-in-human clinical trials.
- cGMP Biomanufacturing Blueprint: A primary facet of the Mayo Clinic collaboration involves adapting HepaTx's manufacturing process to comply with current Good Manufacturing Practice (cGMP) standards. Mayo Clinic’s specialized process development experts handle the creation of standard operating procedures to scale production within state-of-the-art cGMP facilities, establishing a strict quality control and assurance framework required for regulatory filings.
- Clinical Trial Leadership: Under the collaboration, Mayo Clinic will spearhead early-stage clinical trials, managing patient enrollment and leading the clinical evaluation of the cell replacement therapy's safety, tolerability, and initial efficacy in individuals suffering from severe liver damage.
- Genomic Partnerships: Previously, HepaTx partnered with organizations such as Namocell and Takara Bio to utilize single-cell genomics, optimizing cell characterization and ensuring the genetic stability and uniformity of their differentiated hepatocyte-like cells during the development phases.
Corporate History and Structure
Incorporated in 2015, HepaTx Corporation was established by a founding team combining deep expertise in stem cell biology, corporate biotechnology, and translational medicine, including Mark Chao, Pier Federico Gherardini, Bruce R. Davis, and Eric Schuur. Dr. Eric Schuur serves as the company’s President and Chief Executive Officer, guiding its regulatory strategy, corporate fundraising, and operational partnerships.
The company has successfully secured early-stage funding from a variety of venture capital entities, institutional investors, and accelerators, including Y Combinator, Argonautic Ventures, Checkmate Capital, Intbox Ventures, and the QB3 incubator network. Through targeted grants, seed funding rounds, and its modern co-development agreements, HepaTx finances its pre-clinical testing, intellectual property portfolio maintenance, and clinical manufacturing pipelines from its headquarters in California.
